U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07099534) titled 'Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study' on July 25.
Brief Summary: The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare us...